Vikram Sinai Talaulikar: New Evidence on Vaginal Estrogen Therapy in Younger Endometrial Cancer Survivors
Vikram Sinai Talaulikar, Associate Specialist in Reproductive Medicine at UCLH and Hon, Associate Specialist in Reproductive Medicine at UCLH and Hon, shared a post on LinkedIn about a paper by Christine D. Hsu et al. published in Menopause:
“An important study from Hsu et al. which evaluated the utilisation of vaginal oestrogen therapy and outcomes associated with its use among younger endometrial cancer survivors. The study is particularly important as the rates of endometrial cancer have been increasing in younger women in different parts of the world.
This is a cohort study using data from the TriNetX database’s US Collaborative Network, which includes electronic health records and insurance claims data from 68 health care organisations. Women 18-51 diagnosed with endometrial cancer between 2005 and 2023 were included. Researchers used 1:1 propensity score matching to create cohorts with and without vaginal oestrogen therapy in the year after their endometrial cancer diagnosis. They estimated hazard ratios (HRs) with 95% CIs for the primary outcome of endometrial cancer recurrence and assessed the risks of negative control outcomes.
1,412 endometrial cancer survivors with vaginal oestrogen therapy and 23,859 without vaginal oestrogen therapy were identified. After propensity score matching, the vaginal ET and non-ET groups included 1,412 individuals each. The mean follow-up times for the vaginal ET and non-ET groups after matching were 4.54 years and 4.07 years respectively. The mean oestrogen therapy treatment duration was 1.88 years.
Endometrial cancer recurrence risk was not increased among those with vaginal oestrogen use (HR, 0.87; 95% CI, 0.60-1.27).
The authors concluded that endometrial cancer survivors with short-term exposure to vaginal oestrogen therapy did not have an elevated risk of endometrial cancer recurrence compared with those without.
Strengths of the study are diverse large cohort, use of negative controls and more than 4 years follow-up. Limitations include – difficulty in stratifying by tumour stage, using proxy outcome for cancer recurrence, inability to assess oestrogen dose response and short-term treatment duration.
Nevertheless, these are reassuring data for women who are endometrial cancer survivors but find themselves making difficult decisions about use of vaginal oestrogen therapy for genitourinary symptoms of menopause after treatment completion.”
Title: Vaginal estrogen therapy utilization and associated outcomes in younger survivors of endometrial cancer
Authors: Christine D. Hsu, Xiaoying Yu, Gwyn Richardson, Yong-Fang Kuo, Fangjian Guo, Victor Adekanmbi, Thao N. Hoang, Pranay Sharma, Abbey B. Berenson
Read the full article.
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
May 1, 2026, 03:13International Expert Recommendations in Emerging Reproductive Science – ESHRE
-
Apr 30, 2026, 18:45AI in Ultrasound Follicular Monitoring Moves Toward Clinical Decision Support – RBMO
-
Apr 30, 2026, 11:42ASRM Encourages Registration for Conference on Practice Growth and Innovation
-
Apr 30, 2026, 11:26ESHRE and ALPHA Launch Global Survey to Update ART Laboratory KPIs
-
Apr 30, 2026, 11:10Susanne Johnson: Advanced Gynaecology Ultrasound Course Day 2
-
Apr 30, 2026, 11:02Platelets Reduce Oxidative Stress Damage in Human Endometrial Stromal Cells in Vitro – RBMO
-
Apr 30, 2026, 10:57GREEG Day 2026: Elevate Your Ultrasound Expertise – GREEG
-
Apr 30, 2026, 10:49Up to Two-Thirds of Elite Female Athletes Experience Irregular Periods – Fertility Plus
-
Apr 30, 2026, 10:47Applications for the ESHRE5 Young Ambassadors 2026 are Still OPEN, But Not for Long! – ESHRE